Hematologic malignancies are among the most prevalent cancers, with an increasing incidence in recent decades. Genetic and epigenetic alterations play a crucial role in the progression of hematologic malignancies, and understanding these molecular underpinnings will guide the development of targeted agents. Indeed, targeted therapies offer promising alternatives to conventional chemotherapy, improving survival and tolerability, especially in older or vulnerable patients. Despite clinical advances, challenges persist due to relapse, refractory cases, and drug resistance. Synergistic therapy combines treatments for improved outcomes and fewer side effects, providing a comprehensive approach. Additionally, nanotechnology offers new avenues for enhanced treatment and is crucial for innovative targeted treatments, ultimately improving patient outcomes.
The main aim of this Research Topic is to explore the future of hematologic malignancy treatment, emphasizing the discovery of new targets or biomarkers and the development of epigenetic drugs. Combining epigenetic therapies with other anti-cancer treatments shows potential in overcoming limitations of single-drug approaches, reducing drug resistance, and enhancing anti-tumor effects. Nanotechnology also holds promise in hematologic malignancy treatment by improving drug precision, reducing toxicity, and enhancing the immune response. This research aims to uncover recent progress in novel genetic targets and innovative epigenetic drug development, ultimately improving patient prognosis. Diverse treatment approaches, advanced combinations, and precise drug delivery methods are anticipated. Additionally, this research topic seeks to address the challenges and solutions in translating findings from the bench to the bedside.
The scope of this Research Topic includes, but is not limited to, the following themes:
• Discovering Novel Therapeutic Targets for Hematologic Malignancies
• Advancing Epigenetic Small Molecule Drug Design, Synthesis, and Identification for the Treatment of Hematologic Malignancies
• Exploring Novel Epigenetic Drug Delivery Strategies to Improve Therapeutic Effects or Avoid Side Effects
• Developing Novel Epigenetic Drugs Combined with Conventional Chemotherapeutic Agents to Mitigate Side Effects and Combat Resistance in Hematologic Malignancies
We invite authors to submit original research articles, reviews, and brief reports. We especially encourage submissions that provide new insights into the genetic and epigenetic mechanisms underlying hematologic malignancies, as well as those that discuss the clinical implications of these findings. Moreover, manuscripts detailing the development of innovative epigenetic drugs and their potential clinical applications are highly welcome.
Hematologic malignancies are among the most prevalent cancers, with an increasing incidence in recent decades. Genetic and epigenetic alterations play a crucial role in the progression of hematologic malignancies, and understanding these molecular underpinnings will guide the development of targeted agents. Indeed, targeted therapies offer promising alternatives to conventional chemotherapy, improving survival and tolerability, especially in older or vulnerable patients. Despite clinical advances, challenges persist due to relapse, refractory cases, and drug resistance. Synergistic therapy combines treatments for improved outcomes and fewer side effects, providing a comprehensive approach. Additionally, nanotechnology offers new avenues for enhanced treatment and is crucial for innovative targeted treatments, ultimately improving patient outcomes.
The main aim of this Research Topic is to explore the future of hematologic malignancy treatment, emphasizing the discovery of new targets or biomarkers and the development of epigenetic drugs. Combining epigenetic therapies with other anti-cancer treatments shows potential in overcoming limitations of single-drug approaches, reducing drug resistance, and enhancing anti-tumor effects. Nanotechnology also holds promise in hematologic malignancy treatment by improving drug precision, reducing toxicity, and enhancing the immune response. This research aims to uncover recent progress in novel genetic targets and innovative epigenetic drug development, ultimately improving patient prognosis. Diverse treatment approaches, advanced combinations, and precise drug delivery methods are anticipated. Additionally, this research topic seeks to address the challenges and solutions in translating findings from the bench to the bedside.
The scope of this Research Topic includes, but is not limited to, the following themes:
• Discovering Novel Therapeutic Targets for Hematologic Malignancies
• Advancing Epigenetic Small Molecule Drug Design, Synthesis, and Identification for the Treatment of Hematologic Malignancies
• Exploring Novel Epigenetic Drug Delivery Strategies to Improve Therapeutic Effects or Avoid Side Effects
• Developing Novel Epigenetic Drugs Combined with Conventional Chemotherapeutic Agents to Mitigate Side Effects and Combat Resistance in Hematologic Malignancies
We invite authors to submit original research articles, reviews, and brief reports. We especially encourage submissions that provide new insights into the genetic and epigenetic mechanisms underlying hematologic malignancies, as well as those that discuss the clinical implications of these findings. Moreover, manuscripts detailing the development of innovative epigenetic drugs and their potential clinical applications are highly welcome.
